Loading
A FAP-targeted theranostic pair: one version images almost any solid tumour, the other treats it with radiation.
FAP-2286 is a theranostic pair: a cyclic peptide that binds fibroblast activation protein (FAP), linked to a DOTA chelator carrying 68Ga for PET imaging or 177Lu for beta therapy. FAP sits on cancer-associated fibroblasts in the stroma of most solid tumours rather than on cancer cells, so one agent can image and irradiate many tumour types, and the cyclic peptide gives longer tumour retention than the FAPI small molecules used for imaging. Clovis Oncology developed it until its 2022 bankruptcy; Novartis then acquired it via 3B Pharmaceuticals. The 177Lu-FAP-2286 LuMIERE phase 1/2 trial is dose-escalating in cycles every 6 weeks with pancreatic, sarcoma and breast cohorts. For a newcomer: a radioligand aimed at the scaffolding around tumours rather than the tumour cells.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Cyclic peptide FAP binder with DOTA chelator for 68Ga (imaging) or 177Lu (therapy). Connects to FAP.
1.Radioligand circulates and binds FAP on cancer-associated fibroblasts on tumour cells
Source: clinicaltrials.gov/study/NCT04939610. Doses are for orientation; the current label governs.
Novartis acquires rights after Clovis bankruptcy source
| Adverse event |
|---|
| Anaemia |
| Thrombocytopenia |
| Fatigue |
| Nausea |
Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
| Country | Reimbursement | List price | Assistance |
|---|---|---|---|
| United States | Investigational | not disclosed | - |
List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"FAP-2286" OR ABSTRACT:"FAP-2286" OR TITLE:"177Lu / 68Ga" OR ABSTRACT:"177Lu / 68Ga") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FAP-2286 (177Lu / 68Ga), not a curated reading list.
Shares Uwe Haberkorn, FAP theranostics as a pan-cancer stromal strategy, Radiopharmaceutical roadmap: iodine → lutetium → actinium, FAPI PET.
Shares FAP theranostics as a pan-cancer stromal strategy, FAPI PET, FAP, Cold tumours and the immunosuppressive microenvironment.
Shares Invasion: proteases, adhesion & the invasive front, FAPI PET, FAP, Fibroblast activation, desmoplasia & matrix stiffness.
Shares Invasion: proteases, adhesion & the invasive front, FAP, Fibroblast activation, desmoplasia & matrix stiffness, Pancreatic ductal adenocarcinoma.
Shares FAPI PET, FAP, Fibroblast activation, desmoplasia & matrix stiffness, Pancreatic ductal adenocarcinoma.
Shares University Hospital Düsseldorf / CIO Düsseldorf, FAPI PET, FAP.
Shares FAP, Radioligand therapy (beta emitters), Sarcomas (soft tissue, bone, GIST).
Shares FAPI PET, FAP, Triple-negative breast cancer (TNBC).